Clinical trial
A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle…
NCT00383019 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00383019 |
|---|---|
| Title | A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH). |
| Official title | A 8-WEEK, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP, PHASE III STUDY COMPARING THE EFFICACY AND SAFETY OF XALACOM AND XALATAN IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA (POAG) OR OCULAR HYPERTENSION (OH) |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Glaucoma, Ocular Hypertension |
| Intervention type | Drug |
| Interventions | Xalatan, Xalacom |
| Enrollment | 300 |
| Start date | Nov 14, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Oct 2, 2006 |
| Last update posted | Sep 8, 2021 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: